AstraZeneca is set to report its second-quarter results on July 27, and analysts at Bank of America expect the drugmaker to deliver steady, in-line growth. The forecast points to a 7% year-on-year rise in sales to $15.42 billion, with earnings per share climbing 16% to $2.51. But beneath the headline numbers, a familiar story is playing out: blockbuster drugs eventually face competition, and the company's ability to manage that transition will be key for investors.
Oncology Drugs Drive Growth
The main support for AstraZeneca's quarter comes from its oncology portfolio. Bank of America expects continued growth from Tagrisso, a lung cancer treatment, and Imfinzi, an immunotherapy for several cancers. Enhertu, a breast cancer drug developed with Daiichi Sankyo, is also expected to contribute. These drugs are part of AstraZeneca's core growth engine and have been expanding their approved uses over time.
Oncology has become the dominant driver for many large pharmaceutical companies, and AstraZeneca is no exception. Tagrisso alone brought in over $5 billion in sales last year, and Imfinzi has been growing steadily as it gains approvals for additional cancer types. The strength in this segment helps offset weakness elsewhere.
Farxiga Faces Headwinds
The drag on the quarter is Farxiga, a diabetes and heart failure drug that has been a major revenue source for AstraZeneca. Farxiga is now facing two significant pressures: the arrival of cheaper generic versions in the United States, and a roughly 9% government-mandated price cut in Japan. Bank of America models Farxiga sales at around $1.7 billion for the quarter, about 3% below the average analyst estimate.
When a drug loses patent protection, generic competition can quickly erode pricing and volumes. In the US, multiple generic manufacturers have launched copycat versions of Farxiga, putting pressure on AstraZeneca's market share. In Japan, the government regularly resets drug prices to control healthcare costs, and Farxiga's cut is part of that process. These headwinds are not new, but they are intensifying.
Margin Story in Focus
The mix shift between growing oncology sales and declining Farxiga revenue matters for profitability. Bank of America still expects AstraZeneca's operating margin to reach 33.6% in the quarter, up about 1.9 percentage points from a year earlier. However, the bank has trimmed its earnings per share estimates for 2026 through 2028, signaling that the bigger debate is whether management can keep expanding margins in 2027 while replacing Farxiga revenue.
When a mature drug loses exclusivity, the revenue gap must be filled by newer products that often come with higher launch, manufacturing, or marketing costs. That can compress margins in the short term, even if overall sales look healthy. For AstraZeneca, the question is whether its pipeline of oncology drugs and other candidates can generate enough growth to maintain or improve profitability.
What Investors Should Watch
Going into the July 27 update, the quarter's headline sales and earnings may matter less than the company's outlook for 2027 and beyond. Investors will be listening for management's explanation of how it plans to expand margins while Farxiga revenue declines. Pipeline updates, including progress on new drug approvals and clinical trial results, could also move the stock.
The broader market context is also relevant. AstraZeneca is a FTSE 100 component, and the index has been showing mild gains as UK growth steadies. The company's performance can influence sentiment toward the broader UK market, especially for investors focused on healthcare stocks.
For everyday investors, the key takeaway is that even a well-run pharmaceutical company faces the inevitable cycle of drug patent expirations. The ability to manage that transition—by developing new drugs, expanding existing ones, and controlling costs—determines long-term returns. AstraZeneca's Q2 report will offer a window into how well it is navigating that challenge.
Bank of America's estimates suggest a solid quarter, but the real story is about what comes next. As Farxiga fades, the spotlight turns to the next generation of drugs and the company's margin strategy. That is what will likely drive the stock in the months ahead.
